Mylan Inc. has launched potassium chloride extended-release tablets 8 mEq (600 mg) and 10 mEq (750 mg), a medication for people with hypokalemia, or a low potassium level.


Mylan, potassium chloride extended-release tablets, generic version of Klor-Con, hypokalemia, low potassium level, Upsher-Smith






































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Mylan releases Klor-Con generic

August 22nd, 2014

PITTSBURGH – Mylan Inc. has launched potassium chloride extended-release tablets 8 mEq (600 mg) and 10 mEq (750 mg), a medication for people with hypokalemia, or a low potassium level.

Mylan said Friday that its product, which has commenced shipping, is the first generic version of Klor-Con extended-release tablets from Upsher-Smith Laboratories Inc.

Specifically, Mylan's Food and Drug Administration-approved generic product is indicated for the treatment of patients with hypokalemia, with or without metabolic alkalosis; in digitalis intoxication; and in patients with hypokalemic familial periodic paralysis.

Potassium chloride extended-release tablets 8 mEq (600 mg) and 10 mEq (750 mg) had U.S. sales totaling about $135.05 million for the 12 months ended June 30, according to IMS Health data cited by Mylan.

Advertisement